MDxHealth S.A.
MDXH.BR
Euronext Brussels3.02
EUR
-0.12
- -
MDxHealth S.A.
MDXH.BR
(Euronext Brussels)
Recent
price
3.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- MDxHealth SA (MDXH.BR), a commercial-stage precision diagnostics company founded in 2003 and headquartered in Herstal, Belgium, provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases using proprietary genetic, epigenetic, and complex molecular technologies. The company offers a portfolio of tissue-based and liquid biopsy-based tests including ConfirmMDx for addressing prostate biopsy sampling errors and false negatives; SelectMDx for assessing biopsy risk in men with elevated PSA; GPS Prostate for guiding treatment in low- to high-risk localized prostate cancer; ExoDx Prostate, a non-invasive urine-based test for high-grade cancer risk; ResolveMDx for urinary tract infection treatment selection; AssureMDx; InformMDx; and MonitorMDx, targeting urologists, oncologists, and healthcare providers primarily in the United States and Europe. In September 2025, MDxHealth completed the acquisition of Bio-Techne's Exosome Diagnostics business for $15 million in cash and stock, adding the ExoDx Prostate test and enhancing liquid biopsy capabilities with expected contributions exceeding $20 million in revenue by 2026; the company also ceased its germline testing offering to focus on core urologic diagnostics, appointed Michael Holder to its board in July 2025, and reported third-quarter 2025 revenues of $27.4 million, up 18% year-over-year, achieving adjusted EBITDA profitability.